Immunic Hosts Relapsing MS R&D Day
Analysis based on 9 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
The announcement is a routine corporate communication that may generate modest interest among investors tracking Immunic's clinical progress. The upcoming R&D day could provide insights into the potential of vidofludimus calcium, but no immediate market impact is expected.
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company, announced on September 2, 2026 that it will host a virtual research and development (R&D) day focused on relapsing multiple sclerosis (MS) on September 9, 2026. The event will feature management including CEO Ockelbo-Lundgren, CMO Michael A. Panzara, CSO Hella Kohlhof, and President & COO Jason Tay, joined by key opinion leaders Amit Bar-Or of the University of Pennsylvania and Stephen Krieger of the Icahn School of Medicine at Mount Sinai. The R&D day will discuss vidofludimus calcium (IMU-838), an investigational oral therapy combining Nurr1 activation and DHODH inhibition, ahead of the expected top-line data readout from the Phase 3 ENSURE trials in relapsing MS by the end of 2026. The webinar is scheduled from 11:00 am to 12:30 pm ET via Zoom.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard